Literature DB >> 31203999

Clonal Hematopoiesis and risk of Acute Myeloid Leukemia.

Pinkal Desai1, Duane Hassane2, Gail J Roboz2.   

Abstract

Acute Myeloid Leukemia, the most common form of acute leukemia in adults, is an aggressive hematopoietic stem cell malignancy that is associated with significant morbidity and mortality. Though AML generally presents de novo, risk factors include exposure to chemotherapy and/or radiation, as well as both familial and acquired bone marrow failure syndromes. Clonal Hematopoiesis (CH) refers to an expansion of blood or marrow cells resulting from somatic mutations in leukemia-associated genes detected in individuals without cytopenias or hematological malignancies. While CH is considered part of normal ageing, CH is also significantly associated with cardiovascular disease, solid tumors, and hematological malignancies. In this review, we will discuss evidence linking CH with the development of AML, as well as describe challenges in and strategies for monitoring patients with high risk CH mutations.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  ARCH; Acute myeloid leukemia; CHIP; Clonal hematopoiesis; Myelodysplastic syndrome

Year:  2019        PMID: 31203999     DOI: 10.1016/j.beha.2019.05.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  6 in total

1.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newborns.

Authors:  Shu-Hong Lin; Youjin Wang; Stephen W Hartley; Danielle M Karyadi; Olivia W Lee; Bin Zhu; Weiyin Zhou; Derek W Brown; Erin Beilstein-Wedel; Rohan Hazra; Deborah Kacanek; Ellen G Chadwick; Carmen J Marsit; Miriam C Poirier; Sean S Brummel; Stephen J Chanock; Eric A Engels; Mitchell J Machiela
Journal:  AIDS       Date:  2021-08-01       Impact factor: 4.632

Review 3.  Long Non-coding RNAs in Myeloid Malignancies.

Authors:  Alina-Andreea Zimta; Ciprian Tomuleasa; Iman Sahnoune; George A Calin; Ioana Berindan-Neagoe
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

4.  Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes.

Authors:  Arianne M Brandsma; Eline J M Bertrums; Markus J van Roosmalen; Damon A Hofman; Rurika Oka; Mark Verheul; Freek Manders; Joske Ubels; Mirjam E Belderbos; Ruben van Boxtel
Journal:  Blood Cancer Discov       Date:  2021-09

5.  IER3 (IEX-1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients.

Authors:  Shandong Ke; Xin Zhang; Xiuzhi Xiang; Yalan Lu; Hongyu An
Journal:  Int J Lab Hematol       Date:  2021-11-02       Impact factor: 3.450

6.  Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.

Authors:  Xiaofei Mo; Mingge Zhou; Hui Yan; Xueqin Chen; Yuetao Wang
Journal:  Cancer Med       Date:  2021-06-29       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.